



## Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Temporary Member’s Name: Dr. James Hildreth

Committee: Vaccines and Related Products Advisory Committee (VRBPAC)

Meeting Date: December 17, 2020

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the meeting topic: VRBPAC will meet in open session to discuss emergency use authorization (EUA) of the ModernaTX, Inc. COVID-19 Vaccine for the prevention of COVID-19 in individuals 18 years and older, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Clinical Trial Participation	Affected Firm	\$0 - \$ 5,000
II. Other Imputed Interests		
Vaccine Test Site; Meharry Medical College	(b) (4) and NIH/NIAID, Affected Firms	\$500,000 – 750,000

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_/S/\_\_\_\_\_  
Signature

\_\_\_\_12/2/2020\_\_\_\_\_  
Date

James Hildreth, M.D. Ph.D.